Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in MiceAndrea J. Pruijssers, Timothy P. Sheahan, Darius Babusis et al.|Cell Reports|2020Cited by 541
Prodrugs of a 1′-CN-4-Aza-7,9-dideazaadenosine <i>C</i>-Nucleoside Leading to the Discovery of Remdesivir (GS-5734) as a Potent Inhibitor of Respiratory Syncytial Virus with Efficacy in the African Green Monkey Model of RSVRichard L. Mackman, Tomáš Cihlář, Hon C. Hui et al.|Journal of Medicinal Chemistry|2021Cited by 90
Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in miceAlexandra Schäfer, Timothy P. Sheahan, David R. Martinez et al.|Science Translational Medicine|2022Cited by 83
Key Metabolic Enzymes Involved in Remdesivir Activation in Human Lung CellsRuidong Li, Joy Y. Feng, Albert Liclican et al.|Antimicrobial Agents and Chemotherapy|2021Cited by 63
Inhaled remdesivir reduces viral burden in a nonhuman primate model of SARS-CoV-2 infectionMeghan S. Vermillion, Danielle Porter, Eisuke Murakami et al.|Science Translational Medicine|2021Cited by 42